Oncology

Faculty Labs

Our lab investigates the molecular mechanisms driving resistance to targeted therapies in acute myeloid leukemia, with the goal of developing novel treatment strategies to overcome resistance and improve patient outcomes.

Our lab seeks to uncover how RNA biology—particularly RNA binding proteins and alternative splicing—drives aggressive childhood leukemias with recurrent gene rearrangements, aiming to translate these insights into targeted therapies.

Our lab advances personalized therapies for high‑risk pediatric cancers by integrating drug discovery, molecular profiling, and bench‑to‑bedside translational research to improve outcomes for children with leukemia and other cancers.

Our lab works to uncover and target novel molecular drivers of breast cancer—particularly the DEK oncogene—by combining advanced model systems, patient samples, and preclinical therapeutics to improve biomarkers, treatments, and survival outcomes.

Our lab aims to advance our understanding of both HPV-related and -unrelated squamous cell carcinoma development, and to develop new approaches to the diagnosis and treatment of HPV as a major cause of cancer worldwide.

Our lab aims to uncover how developmental and hepatobiliary lineage programs drive the initiation and growth of pediatric liver cancers, particularly hepatoblastoma, to reveal new biological paradigms and therapeutic strategies for these challenging tumors.